Interim CEO Named Permanent Leader at Tango Therapeutics Post author:Sam Post published:September 24, 2017 Post category:BioPharma September 25, 2017By Mark Terry, BioSpace.com Breaking News… Source: BioSpace You Might Also Like FDA Hails Novartis' Kisqali a Breakthrough January 2, 2018 Rhythm Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters??? Option To Purchase Additional Shares October 10, 2017 What Biogen CFO's Departure Means for Company's M&A Strategy June 14, 2017
Rhythm Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters??? Option To Purchase Additional Shares October 10, 2017
